Results 1 to 10 of about 230 (101)
Aprocitentan: A new development of resistant hypertension [PDF]
Journal of Clinical Hypertension, 2023 As the blood pressure threshold for commencing antihypertensive treatment diminishes, the cohort suffering from resistant hypertension (RH) correspondingly expands.
Yao Yao Mm
exaly +5 more sources
Aprocitentan: New insights [PDF]
Frontiers in Cardiovascular Medicine, 2022 Fahimeh Varzideh +2 more
exaly +6 more sources
Current Knowledge About Aprocitentan in Hypertension [PDF]
International Journal of Molecular SciencesHypertension (HT) is the leading contributor to the global burden of disease and overall mortality and is expected to increase due to such factors as increased life expectancy and rising obesity rates. Although HT significantly contributes to cardiovascular disease, it is also considered one of the most modifiable risk factors.
Daniela Grimm +2 more
exaly +5 more sources
Journal of Clinical Hypertension, 2022 The design and baseline data of the PRECISION study, which evaluates the effect of the dual endothelin receptor antagonist aprocitentan on blood pressure (BP) in patients with resistant hypertension (RHT) are presented. The study is a blinded, randomized,
Ji-Guang Wang +2 more
exaly +6 more sources
Aprocitentan: a new emerging prospect in the pharmacotherapy of hypertension
Blood PressureBackground Resistant hypertension (RH) is linked to higher risks of cardiovascular events and there remains an unmet therapeutic need driven by pathophysiologic pathways unaddressed by guideline-recommended therapy.
Lina Naseralallah, Somaya Koraysh
exaly +5 more sources
Journal of Cardiovascular Pharmacology and TherapeuticsIntroduction Aprocitentan, is an orally active, once-daily administered, dual endothelin receptor antagonist that was recently approved for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult ...
Patricia N Sidharta, Janneke M Brussee
exaly +4 more sources
Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials [PDF]
Reviews in Cardiovascular MedicineBackground: Hypertension is one of the most prevalent disorders encountered in medical practice, yet effective pharmacotherapy options for resistant hypertension are limited. In this meta-analysis, we aimed to evaluate the efficacy and
Li Zheng +4 more
doaj +2 more sources
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment [PDF]
Scientific Reports, 2022 The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerability of the dual endothelin receptor antagonist aprocitentan was clinically investigated as 25% of aprocitentan is cleared through the liver.
Magda S. C. Fontes +4 more
doaj +2 more sources
Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension [PDF]
Life, 2023 Resistant hypertension (RH) is defined as the failure to achieve blood pressure control despite using triple combination therapy with a renin-angiotensin system inhibitor (RAS-i), a calcium antagonist, and a diuretic.
Chrysoula Boutari, Fotios Siskos
doaj +2 more sources
Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension. [PDF]
HypertensionBACKGROUND: Hypertension is a cause and consequence of chronic kidney disease (CKD). Resistant hypertension is common and often difficult to control in patients with CKD. This post hoc analysis evaluated the efficacy and safety of aprocitentan (with standardized background antihypertensive therapy) in patients ...
Rossignol P +10 more
europepmc +3 more sources